(89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kinase inhibitor lapatinib can induce a compensatory HER3 increase, which may attenuate antitumor efficacy. Therefore, we explored in vivo HER3 tumor status assessment after lapatinib treatment with zirco...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Pool, Martin, Kol, Arjan, de Jong, Steven, de Vries, Elisabeth G. E., Lub-de Hooge, Marjolijn N., Terwisscha van Scheltinga, Anton G.T.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5680796/
https://ncbi.nlm.nih.gov/pubmed/28873009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2017.1371382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados